(Q43796125)

26 November 2017

title

Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). (English)

1 reference

26 November 2017

1 reference

8

A M Lincoff

1 reference

26 November 2017

9

R M Califf

1 reference

26 November 2017

J E Tcheng

1

1 reference

26 November 2017

J D Talley

2

1 reference

26 November 2017

J C O'Shea

3

1 reference

26 November 2017

I C Gilchrist

4

1 reference

26 November 2017

N S Kleiman

5

1 reference

26 November 2017

C L Grines

6

1 reference

26 November 2017

C J Davidson

7

1 reference

26 November 2017

L K Jennings

10

1 reference

26 November 2017

M M Kitt

11

1 reference

26 November 2017

T J Lorenz

12

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 November 2001

1 reference

American Journal of Cardiology

26 November 2017

published in

1 reference

26 November 2017

volume

88

1 reference

26 November 2017

issue

10

1 reference

26 November 2017

page(s)

1097-1102

1 reference

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902041-0

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902041-0

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902041-0

Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902041-0

Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902041-0

Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902041-0

Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902041-0

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902041-0

THE AGGREGATION OF BLOOD PLATELETS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902041-0

Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902041-0

Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902041-0

Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902041-0

Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902041-0

Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902041-0

Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902041-0

Ligand and cation binding are dual functions of a discrete segment of the integrin β3 subunit: Cation displacement is involved in ligand binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902041-0

10.1016/S0002-9149(01)02041-0

7 January 2021

Identifiers

DOI

1 reference

26 November 2017

1 reference